Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | CD2 | P06729 | 1/20 | 0.47 |
| ▸ | CD58 | P19256 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 14/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.46 |
| ▸ | TCF4 | P15884 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19367903 | 0.97 | ERBB2 (0.60) | ERBB2CD2CD58PIN1ITGB3 | |
| SCHEMBL19375812 | 0.92 | CD2 (0.54) | ERBB2CD2CD58ITGB3ITGB1 | |
| SCHEMBL19367902 | 0.89 | CD2 (0.53) | ERBB2CD2CD58ITGB3ITGB1 | |
| SCHEMBL19367901 | 0.87 | ERBB2 (0.70) | ERBB2PIN1ITGB3ITGB1ITGAV | |
| SCHEMBL29666771 | 0.77 | ERBB2 (0.57) | ERBB2ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL30037692 | 0.76 | ITGAV (0.60) | ERBB2PIN1ITGB3ITGB1ITGAV | |
| SCHEMBL29666785 | 0.76 | HDAC4 (0.60) | ERBB2PIN1ITGB3ITGB1ITGAV | |
| SCHEMBL29666836 | 0.75 | HDAC4 (0.57) | ERBB2ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL29666726 | 0.75 | ITGAV (0.56) | ERBB2PIN1ITGB3ITGB1ITGAV | |
| SCHEMBL29666877 | 0.74 | HDAC4 (0.56) | ERBB2PIN1ITGB3ITGB1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963486-B2 | Peptidomimetics for treating HER2-overexpressed cancer | Board of Supervisors for the University of Louisiana System (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170267725-A1 | Peptidomimetics for Treating HER2-Overexpressed Cancer | Board of Supervisors for the University of Louisiana System (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267725-A1 | Peptidomimetics for Treating HER2-Overexpressed Cancer | ERBB2, EGFR, ERBB3 | ERBB2 1/4885CD2 3672/4885CD58 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.